Showing posts with label Allergy. Show all posts
Showing posts with label Allergy. Show all posts

Saturday, September 28, 2013

0 Celebrating allergy research in Canada

Celebrating allergy research in Canada













The 2012 annual scientific meeting of the Canadian Society of Allergy and Clinical Immunology in Calgary last month was a fantastic event bringing clinicians, allergists, researchers and health professionals together to uncover and discuss the latest developments within the field. Food allergy and anaphylaxis remain high on the agenda, along with asthma as these continue to increase in prevalence throughout the population.
This was also an opportunity to recognise the quality and importance of the research being carried out by Canadian Allergists, with 5 category awards for posters presented at the conference. The conference abstracts were published in Allergy, Asthma & Clinical Immunology and are available to view and download.
Lively discussions surrounded a review of coroners’ cases that confirmed no paediatric anaphylactic deaths in Ontario in the last decade, as well as the infrequent but recurring case reports of anaphylaxis due to bacitracin ointment exposure. Presentations on the continuing challenges of oral immunotherapy in the treatment of food allergy, due to a high rate of systemic reactions to treatment, and quality of life issues for children and adolescents with allergic disorders also received a lot of attention.
Ultimately, only one winner could be chosen in each category, but all are to be congratulated for their hard work and dedication to allergy research!
Allergy & Anaphylaxis: 
1st place – Joanne Yeung, McGill University: “Oral immunotherapy for milk allergy: a systematic review”
2nd place – Sophia Xu, McMaster University: “Anaphylaxis Deaths in Ontario: A retrospective review of cases from 1986 to 2011”
Honorable mention – Mary McHenry, Dalhousie University: “Impact of primary food allergies on the introduction of other foods amongst Canadian children”
Honorable mention – Gina Tsai, Western University: “Tree Pollen Allergy in Southwestern Ontario”
Allied Health
1st place – Doug Houlbrook, University of Manitoba, “Parental asthma diagnosis and age of onset as a risk factor in child’s asthma”
2nd place – Lesley Stewart, The Children’s Asthma Education Centre: ““What Bugs Me”: Children’s lived experience of asthma”
Asthma/Allergic Rhinitis:
1st place – Elinor Simons, University of Toronto: “Associations between second-hand smoke exposure in pregnancy and age of childhood asthma development”
2nd place – Arunmozhi Dominic, University of Western Ontario: “Measured depth of subcutaneous tissue on posterolateral arm of aeroallergen immunotherapy patients”
Basic Science/Immunology:
Meghan Azad, University of Alberta: “Infant gut microbiota and the hygiene hypothesis of allergic disease”
Case Reports:
1st place – Hugo Chapdelaine, University of Montreal: “Experience with subcutaneous immunoglobulin therapy in two pediatric cases of immune thrombocytopenia purpura”
2nd place – Christine Song, University of Toronto: “Infliximab-graded challenge in a patient with Crohn’s disease and adalimumab hypersensitivity”
Special thanks to Dr Anne Ellis for her assistance with this blog post.


BioMed Central blog






0 Update in clinical allergy and immunology









Keywords:




  • asthma;

  • atopic dermatitis;

  • clinical immunology;

  • eosinophils;

  • innate immunity






Abstract




In the recent years, a tremendous body of studies has addressed a broad variety of distinct topics in clinical allergy and immunology. In this update, we discuss selected recent data that provide clinically and pathogenetically relevant insights or identify potential novel targets and strategies for therapy. The role of the microbiome in shaping allergic immune responses and molecular, as well as cellular mechanisms of disease, is discussed separately and in the context of atopic dermatitis, as an allergic model disease. Besides summarizing novel evidence, this update highlights current areas of uncertainties and debates that, as we hope, shall stimulate scientific discussions and research activities in the field.





Research progress goes ahead fast, and each issue of Allergy distributes a dozen of new and interesting papers providing actual research results, opinions and reviews in different fields of allergy and clinical immunology. Over time, it becomes difficult to keep an overview on the novelties and trends given by these articles. Here, we give an update aiming to summarize interesting papers published in Allergy over the last years and putting them in context with recently published work in the field. As we were not able to cover all fields, we selected three research subjects: (i) Hygiene hypothesis: the role of the microbiome in allergy; (ii) Pathogenic mechanisms of allergic diseases and their potential therapeutic implications; (iii) Atopic dermatitis (AD): skin barrier and allergic inflammation. In our view, the selected papers provide new insights in clinically and pathogenetically important research as well as novel targets and strategies for therapy that might become starting points for future research.





Thursday, September 26, 2013

0 Endotypes and phenotypes of chronic rhinosinusitis: A PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology








The Journal of Allergy and Clinical Immunology
Volume 131, Issue 6 , Pages 1479-1490, June 2013



Endotypes and phenotypes of chronic rhinosinusitis: A PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology





Received 31 October 2012; received in revised form 11 February 2013; accepted 14 February 2013. published online 15 April 2013.



Chronic rhinosinusitis (CRS) is a complex disease consisting of several disease variants with different underlying pathophysiologies. Limited knowledge of the mechanisms of these disease subgroups is possibly the greatest obstacle in understanding the causes of CRS and improving treatment. It is generally agreed that there are clinically relevant CRS phenotypes defined by an observable characteristic or trait, such as the presence or absence of nasal polyps. Defining the phenotype of the patient is useful in making therapeutic decisions. However, clinical phenotypes do not provide full insight into all underlying cellular and molecular pathophysiologic mechanisms of CRS. Recognition of the heterogeneity of CRS has promoted the concept that CRS consists of multiple groups of biological subtypes, or “endotypes,” which are defined by distinct pathophysiologic mechanisms that might be identified by corresponding biomarkers. Different CRS endotypes can be characterized by differences in responsiveness to different treatments, including topical intranasal corticosteroids and biological agents, such as anti–IL-5 and anti-IgE mAb, and can be based on different biomarkers that are linked to underlying mechanisms. CRS has been regarded as a single disease entity in clinical and genetic studies in the past, which can explain the failure to identify consistent genetic and environmental correlations. In addition, better identification of endotypes might permit individualization of therapy that can be targeted against the pathophysiologic processes of a patient’s endotype, with potential for more effective treatment and better patient outcomes.



 



 Disclosure of potential conflict of interest: C. A. Akdis receives research support from Novartis, PREDICTA, the Swiss National Science Foundation, MeDALL, the Global Allergy and Asthma European Network, and the Christine Kühne-Center for Allergy Research and Education; has consulted for Actellion, Aventis, Stallergenes, and Allergopharma; is president of the European Academy of Allergy and Clinical Immunology; is a fellow and interest group member of the American Academy of Allergy, Asthma & Immunology (AAAAI); is a former committee member of the Global Allergy and Asthma European Network; and is the director of the Christine Kühne-Center for Allergy Research and Education. C. Bachert has received research support from Novartis and GlaxoSmithKline. M. S. Dykewicz has consultant arrangements with Boehringer Ingelheim, Ista, and Merck. R. M. Naclerio has received travel support from AAAAI; has board memberships with Merck, TEVA, and Sunovion; has received grants from TEVA, Johnson & Johnson, and Kalypsis; and has received payment for lectures from TEVA and Sunovion. R. P. Schleimer has consultant arrangements with Intersect ENT, GlaxoSmithKline, Allakos, and Aurasense; has received research support from the National Institutes of Health; and has received stock/stock options from Allakos. D. Ledford has received travel support from AAAAI; has consultant arrangements with Genentech; and has received payment for lectures from Meda and Genentech. The rest of the authors declare that they have no relevant conflicts of interest.

PII: S0091-6749(13)00367-9

doi:10.1016/j.jaci.2013.02.036





The Journal of Allergy and Clinical Immunology
Volume 131, Issue 6 , Pages 1479-1490, June 2013



Wednesday, September 25, 2013

The Washington Manual® Allergy, Asthma, and Immunology Subspecialty Consult for PDA Free

The Washington Manual® Allergy, Asthma, and Immunology Subspecialty Consult for PDA

Author: Washington University School of Medicine Department of Medicine
Edition: Cdr
Binding: Audio CD
ISBN: 0781748933






The Washington Manual® Allergy, Asthma, and Immunology Subspecialty Consult for PDA: Powered by Skyscape, Inc. (The Washington Manual® Subspecialty Consult Series)



Prepared by residents and fellows with senior faculty advisors at the Washington University School of Medicine, this handy quick reference outlines current concepts and practice guidelines in the rapidly evolving fields of allergy, asthma, and immunology.


It covers both inpatient and outpatient approaches with the same front-lines practicality as the world-famous Washington ManualA of Medical Therapeutics. Symptom-oriented and disease-oriented entries cover both acute and chronic problems, including drug allergy, anaphylaxis, eosinophilia, immunodeficiency, and latex allergy. Coverage also includes commonly used allergy and asthma drugs, laboratory values for tests in immunology, and a sample schedule for perennial aqueous immun


download



Internal Medicine The Washington Manual® Allergy, Asthma, and Immunology Subspecialty Consult for PDA



It covers both inpatient and outpatient approaches with the same front-lines practicality as the world-famous Washington ManualA of Medical Therapeutics
Coverage also includes commonly used allergy and asthma drugs, laboratory values for tests in immunology, and a sample schedule for perennial aqueous immun



Related Books




Monday, September 23, 2013

0 Development of children"s hymenoptera venom allergy quality of life scale (CHVAQoLS)

Open Access


Research


Development of children’s hymenoptera venom allergy quality of life scale (CHVAQoLS)



Ewa Cichocka-Jarosz, Piotr Brzyski, Beata Tobiasz-Adamczyk, Grzegorz Lis and Jacek J Pietrzyk










For all author emails, please log on.








Clinical and Translational Allergy 2013, 3:25 doi:10.1186/2045-7022-3-25

Published: 1 August 2013





Abstract (provisional)


Background


Venom allergy is a rare but life-threatening disease and may have a considerable impact on the health-related quality of life (HRQoL) of patients, especially children. This paper presents development of the HRQoL scale for children and adolescents with Hymenoptera venom allergy (HVA).

Methods


The study sample consisted of 71 children, born between 1992 and 2000, who presented with a history of insect sting reaction when referred for consultation in the allergy center of Polish-American Children’s Hospital, Krakow, Poland, during the period from 2000 to 2010. The initial pool of 60 items – divided into 6 domains – was prepared. The items with intercorrelations higher than 0.7 were removed from each domain and then principal component analysis was conducted for each domain separately, to provide a one-dimensional subscale for each domain. Reliability of the subscales was assessed using Cronbach alpha coefficient in terms of Classical Test Theory and with rho coefficient in terms of Item Response Theory. The multidimensionality of the scale was tested using multi-trait scaling.

Results


Three to four items from each domain were subsequently selected to constitute six subscales. Rho coefficients for all the subscales reached 0.8, similar results were achieved with the Cronbach alpha coefficients. Multi-trait method showed that the majority of the items indicated stronger correlations with their own subscales than with other subscales, which proves that our constructed subscales measure different dimensions of HRQoL.

Conclusions


The presented scale comprises high validity and reliability subscales measuring six dimensions of HRQoL related to Hymenoptera venom allergy in children and adolescents. Such information may be useful in everyday clinical practice.






The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.



Thursday, September 19, 2013

Anti Allergy Drugs and steroids

Anti-allergy drugs are sometimes called mast cell stabilizers, and suppress the allergic reaction in the bud by damping the activity of mast cells. This medication can control the eyes hay fever and a runny nose, as well as for asthma. It is usually taken as a nasal spray or eye drops. Itchy red, sore eyes and can be alleviated with eye drops sodium turning chromium. A new drug, amide acting honors in a similar way.





Steroids work in the same way as drugs for asthmapreventing inflammation. In a nasal spray that reduces inflammation of the lining of the nose and so avoid a runny nose, nasal congestion and sneezing. You can also avoid the eyes red and itchy. If you suffer from severe hay fever, doctors recommend that you stop taking steroids every day to start again just before the hay fever season and continue until the end of them.





INSINKERATOR GARBAGE DISPOSAL



Corticosteroids are available in tablet form and can also injected steroids. Most decongestantsbelong to a group of drugs called mimetic sympathy. They work by shrinking blood vessels in the nose, reducing congestion and making it easier for you to breathe. They are usually used as a nasal spray, with the result that only a small amount of the drug enters the bloodstream.




Anti Allergy Drugs and steroids




On Sale DISPOSAL ELBOW IN-SINKERATOR






DISPOSAL ELBOW IN-SINKERATOR Review










DISPOSAL ELBOW IN-SINKERATOR Feature




  • “PLUMB PAK” GARBAGE DISPOSAL DRAIN ELBOW

  • For in-sink-erator disposers.

  • Plastic.

  • Hangtag.

  • Black finish.


DISPOSAL ELBOW IN-SINKERATOR Overview



For In-Sink-Erator disposers. Hang tag





Customer Reviews



*** Product Information and Prices Stored: Sep 05, 2011 08:44:11







DISPOSAL ELBOW IN-SINKERATOR



However, if an excessive use of aerosol sprays, decongestant tablets or take, have few side effects, such as increased heart rate and tremors. A dry powder inhaler is convenient to carry, easy to use andable to provide rapid relief of symptoms of asthma.



Anti Allergy Drugs and steroids



Wednesday, September 18, 2013

0 An Important Role of Blood and Lymphatic Vessels in Inflammation and Allergy



Logo of jallerg










J Allergy (Cairo). 2013; 2013: 672381.

Published online 2013 January 31. doi:  10.1155/2013/672381





PMCID: PMC3574757





An Important Role of Blood and Lymphatic Vessels in Inflammation and Allergy








Abstract



Angiogenesis and lymphangiogenesis, the growth of new vessels from preexisting ones, have received increasing interest due to their role in tumor growth and metastatic spread. However, vascular remodeling, associated with vascular hyperpermeability, is also a key feature of many chronic inflammatory diseases including asthma, atopic dermatitis, psoriasis, and rheumatoid arthritis. The major drivers of angiogenesis and lymphangiogenesis are vascular endothelial growth factor- (VEGF-)A and VEGF-C, activating specific VEGF receptors on the lymphatic and blood vascular endothelium. Recent experimental studies found potent anti-inflammatory responses after targeted inhibition of activated blood vessels in models of chronic inflammatory diseases. Importantly, our recent results indicate that specific activation of lymphatic vessels reduces both acute and chronic skin inflammation. Thus, antiangiogenic and prolymphangiogenic therapies might represent a new approach to treat chronic inflammatory disorders, including those due to chronic allergic inflammation.



Formats: